Even with two doses of the MMR vaccine, about 3% of people never develop full protection against measles. That small but real gap exists because vaccination and immunity aren’t the same thing. The vaccine gives your immune system the instructions, but several biological factors determine whether your body actually builds and keeps a lasting defense.
How Effective the Vaccine Actually Is
A single dose of the measles vaccine is about 93% effective at preventing infection. A second dose pushes that to roughly 97%. Those are strong numbers at a population level, but they mean that for every 100 people who get both shots, around 3 will remain vulnerable. During a recent U.S. outbreak with over 1,000 confirmed cases where vaccination status was known, 86% of patients were unvaccinated, 7% had received one dose, and 7% were fully vaccinated with two doses. So breakthrough cases do happen, and they’re not unusual in large outbreaks.
Primary Vaccine Failure: Your Body Never Responded
The most common reason a vaccinated person lacks immunity is that their immune system simply didn’t respond to the vaccine in the first place. This is called primary vaccine failure, and it means the body never produced enough antibodies after the shot. It’s not a flaw in the vaccine itself. It’s a mismatch between the vaccine and that particular person’s biology at that particular moment.
Several things increase the chance of this happening. The biggest one is age at vaccination. Children vaccinated before their first birthday have significantly higher failure rates. In one study of a measles epidemic in São Paulo, every single patient who had been vaccinated before age one showed primary vaccine failure. Among those vaccinated after their first birthday, about 44% of single-dose recipients and 12.5% of two-dose recipients still failed to develop immunity.
Why Vaccination Age Matters So Much
Newborns inherit measles antibodies from their mother during pregnancy. These borrowed antibodies protect the infant for the first few months of life, but they also interfere with vaccination. If a baby receives the measles vaccine while maternal antibodies are still circulating, those antibodies can neutralize the weakened virus in the vaccine before the baby’s own immune system has a chance to learn from it.
The timing of this window is tricky. Research from Laos tracked antibody levels in infants from birth onward. At birth, nearly 98% of babies had protective antibody levels. By four months, more than 71% had lost that protection. By nine months, when the first vaccine dose is typically scheduled, over 86% were no longer protected. So there’s a gap of several months where infants are vulnerable but too young to vaccinate effectively. Giving the vaccine at six months produces a seroconversion rate of only about 76%, compared to 92% at nine months. That’s why most countries schedule the first dose around 12 months, balancing the need for early protection against the risk that maternal antibodies will block the vaccine from working.
Your Genetics Play a Larger Role Than You’d Think
Your genes have a surprisingly strong influence on how well you respond to the measles vaccine. A study of twins found that 88.5% of the variation in measles antibody levels was heritable. In other words, your genetic makeup is the single biggest predictor of whether you’ll mount a strong or weak response.
The key players are a set of immune system genes that control how your cells recognize and respond to foreign invaders. These genes determine which pieces of the measles virus your immune cells grab onto and present to the rest of your immune system, and that in turn shapes which protective signals get sent. Some gene variants lead to robust production of the signals that drive a strong immune response. Others favor signals that dampen it. You don’t get to choose which versions you carry, and there’s currently no routine way to screen for them before vaccination. This genetic lottery is one reason why a small percentage of healthy, properly vaccinated people simply don’t build adequate immunity.
Secondary Vaccine Failure: Immunity That Fades
Even if the vaccine worked perfectly at first, protection can slowly erode over decades. This is secondary vaccine failure, and it’s distinct from never responding at all. Your antibody levels gradually decline until they drop below the threshold needed to fight off infection.
The good news is that this process is very slow. A large modeling study in England estimated waning at roughly 0.04% per year. But over 20 or 30 years, it adds up. Data from outbreaks in France showed vaccine effectiveness dropping from 99.6% right after the second dose to 96.7% sixteen years later. In Berlin, effectiveness fell from 99% to about 91% in adults aged 31 to 40 who had been vaccinated 25 to 30 years earlier. Immunological studies from Canada, Japan, and the Czech Republic have confirmed declining antibody levels in young adults vaccinated more than 20 years ago.
Notably, people who gained immunity from a natural measles infection don’t show this same decline. The wild virus triggers a more intense immune response than the weakened vaccine virus, creating longer-lasting memory. That doesn’t mean infection is preferable (measles carries serious risks), but it does explain why waning immunity is primarily a concern in vaccinated populations rather than in older generations who had measles as children.
Cold Chain Breaks and Vaccine Handling
The measles vaccine contains a live but weakened virus, and that virus needs to stay viable to work. If the vaccine is exposed to excessive heat or isn’t stored properly, the virus can lose potency before it’s ever injected. The technical term for this is a cold chain failure. In its freeze-dried form, the vaccine holds up reasonably well: it stays above minimum potency for about six days at body temperature (37°C) or two days at 40°C. But once it’s mixed with the liquid diluent for injection, it becomes far more fragile. In well-resourced healthcare systems, cold chain failures are rare. In areas with unreliable refrigeration or long supply routes, they become a more significant factor.
What You Can Do About It
If you’ve been told you’re not immune to measles despite vaccination, a blood test measuring your measles IgG antibody levels is the standard way to confirm it. Levels below 0.18 IU/mL are generally considered seronegative, meaning you have no meaningful protection. Levels between that threshold and about 1.0 IU/mL are considered low and may not reliably prevent infection.
An additional dose of the MMR vaccine is a straightforward option. Research comparing a third dose in young adults (ages 18 to 25) found that measles antibody levels rose about 1.8-fold within a month and remained elevated a year later. Seroprotection rates for measles were already 97% before the third dose in that study group and reached 100% afterward. Even more encouraging, antibody levels after a third dose appeared to decline more slowly than after a second dose. For someone identified as a non-responder or someone whose immunity has waned, an additional dose can close the gap.
If you’re unsure of your vaccination history or your records are incomplete, the simplest path is to get another dose. There’s no medical risk to receiving an extra MMR shot even if you’re already immune. Your existing antibodies will simply neutralize the vaccine virus, and you’ll get a mild boost at most.